Loading...
Market
What will be Guardant Health's position in the colorectal cancer screening market by July 29, 2025?
2
Resolution / Starting Odds
Guardant Health becomes the market leader • 25%
Guardant Health is among the top 3 • 25%
Guardant Health remains in the top 5 • 25%
Guardant Health does not make it to the top 5 • 25%
Market analysis reports from industry analysts
Story
FDA Approves Guardant Health's Shield™ Colorectal Cancer Blood Test on Monday
Jul 29, 2024, 11:00 AM
The U.S. Food and Drug Administration (FDA) has approved Guardant Health's Shield™ blood test as a primary screening option for colorectal cancer. This approval on Monday not only facilitates Medicare reimbursement but also marks a significant advancement in colorectal cancer screening. Guardant Health's blood-based cancer test aims to detect cancer that begins in the colon or rectum, providing a non-invasive alternative to traditional screening methods.
View original story
Similar markets
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Guardant Health • 25%
Roche • 25%
Illumina • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
Above $300 million • 25%
Guardant Health's Shield • 25%
Exact Sciences' Cologuard • 25%
Epigenomics' Epi proColon • 25%
Other • 25%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Guardant Reveal • 25%
Guardant360 • 25%
GuardantOMNI • 25%
None • 25%
Positive results for Shield • 25%
Positive results for Reveal • 25%
Positive results for Guardant360 • 25%
No positive results • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%